Haleon plc Publishes EMTN Programme Supplement
Ticker: HLNCF · Form: 6-K · Filed: Sep 9, 2024 · CIK: 1900304
Sentiment: neutral
Topics: debt-program, filing-update
TL;DR
Haleon dropped a supplement for its EMTN program, check the details.
AI Summary
Haleon plc announced on September 9, 2024, the publication of a supplement to its Euro Medium Term Note (EMTN) Programme. This filing, a Form 6-K, serves as a report of foreign private issuer information for the month of September 2024.
Why It Matters
This filing updates information related to Haleon's EMTN Programme, which could impact investors' understanding of the company's debt issuance capabilities and financial structure.
Risk Assessment
Risk Level: low — The filing is a routine update to an existing debt program and does not indicate any immediate financial distress or significant new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former Company Name
- September 9, 2024 (date) — Filing Date and Publication Date
FAQ
What is the purpose of the Form 6-K filing?
The Form 6-K is a report of foreign private issuer information filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What specific document was published by Haleon plc on September 9, 2024?
Haleon plc published a supplement to its EMTN Programme, as indicated by Exhibit 99.1.
What is Haleon plc's former company name?
Haleon plc's former company name was DRVW 2022 Ltd.
What is Haleon plc's fiscal year end?
Haleon plc's fiscal year ends on December 31.
What is the SEC file number for Haleon plc?
The SEC file number for Haleon plc is 001-41411.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 14.1 · Accepted 2024-09-09 09:54:16
Filing Documents
- a4155d.htm (6-K) — 25KB
- 0001654954-24-011609.txt ( ) — 26KB
From the Filing
PROGRAMME: PUBLICATION OF SUPPLEMENT a4155d UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description           99.1  09 September 2024- “EMTN Programme: publication of supplement”   99.1   EMTN programme: publication of supplement   9 September 2024:  Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the supplement (the "Supplement") to the base listing particulars (together with the Supplement, the "Base Listing Particulars") dated 3 May 2024 regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note Programme, guaranteed by the Company, has been published.   A copy of the Supplement, together with the Base Listing Particulars, is available for inspection at and can be downloaded from:   www.haleon.com/investors/debt-investors   Amanda Mellor Company Secretary   Enquiries   Investors Media   Sonya Ghobrial     +44 7392 784784 Zoe Bird +44 7736 746167 Rakesh Patel        +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562       Email:  investor-relations@haleon.com     Email:   corporate.media@haleon.com     About Haleon   Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit www.haleon.com.     Disclaimer   Please note that the information contained in the Base Listing Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Listing Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Listing Particulars is not addressed.  Prior to relying on the information contained in the Base Listing Particulars, you must ascertain from the Base Listing Particulars whether or not you are part of the intended addressees of the information contained in the Base Listing Particulars.   Your right to access this service is conditional upon complying with the above requirement.   SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 09, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary